Clinical trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When…
NCT04472598 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT04472598 |
|---|---|
| Title | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1) |
| Acronym | TRANSFORM-1 |
| Lead sponsor | AbbVie, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelofibrosis (MF) |
| Intervention type | Drug |
| Interventions | Navitoclax, Ruxolitinib, Placebo for Navitoclax |
| Enrollment | 252 |
| Start date | Sep 29, 2020 |
| Primary completion | Apr 13, 2023 |
| Completion | Jan 29, 2025 |
| First posted | Jul 15, 2020 |
| Last update posted | Feb 21, 2025 |
| Countries | Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan and 13 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: